Peptide education
Pramlintide
Pramlintide acetate · SYMLIN · SymlinPen
Pramlintide is a prescription medicine that acts like amylin, a hormone released with insulin around meals. The US SYMLIN label describes use with mealtime insulin in selected adults with type 1 or type 2 diabetes who have not achieved their desired glucose control. AstraZeneca has discontinued US production and supply of SymlinPen.
SYMLIN can help selected insulin-treated patients manage glucose around meals, but taking it with insulin increases the risk of severe low blood sugar. The drug and insulin plan require clinical supervision.
Overview
Quick answer
Pramlintide is an amylin analogue, not insulin and not a GLP-1 drug. Its diabetes indication is not an approval for weight loss, even though weight changes were measured in diabetes trials.
What does pramlintide do?
It slows stomach emptying, reduces the rise in glucagon after a meal, and affects fullness. These effects help explain its impact on post-meal glucose when it is used with insulin.
Who is it approved for?
The US label describes adjunctive use in people with type 1 or type 2 diabetes who use mealtime insulin but have not reached their desired glucose control despite optimal insulin therapy. The label advises against considering patients with HbA1c above 9% or recurrent severe hypoglycemia requiring assistance in the previous six months. Other selection criteria also apply. Pediatric safety and effectiveness have not been established.
Is SymlinPen available in the US?
AstraZeneca says it has discontinued US production and supply of SymlinPen and expects remaining inventory to run out. FDA records the product's prior approval and lists its marketing status as discontinued. Supply and approval are separate questions; local pharmacy stock has not been verified here.
Is it a weight-loss medicine?
Weight changed in some diabetes studies, but the SYMLIN label is for adjunctive diabetes treatment, not weight loss.
What is the main safety concern?
SYMLIN has a boxed warning for severe hypoglycemia when used with insulin, particularly in type 1 diabetes. The full label says episodes associated with SYMLIN usually occur within the first 2 to 3 hours after injection. That timing is not a guaranteed safety window.
Can it replace insulin?
No. It is an add-on to mealtime insulin. The label calls for insulin and pramlintide adjustments under the direction of a clinician skilled in insulin use.
Evidence
Evidence snapshot
A 52-week trial in 480 people receiving insulin found a greater HbA1c reduction with pramlintide than placebo. An optional open-label extension included some participants who completed the randomized phase.
In a 656-person, 52-week trial, the 120 mcg twice-daily arm showed improved HbA1c and a lower mean weight relative to placebo.
The US label describes use when desired glucose control has not been achieved despite optimal insulin therapy. It does not list weight loss as an indication.
AstraZeneca reports that it has stopped US production and supply. FDA lists the products' marketing status as discontinued; this is distinct from the product's prior approval and labeled indication.
Severe hypoglycemia can occur, particularly in people with type 1 diabetes. Patient selection, glucose monitoring, and clinician-directed insulin adjustment matter.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Pramlintide can be used instead of insulin. | The cited diabetes studies evaluated pramlintide as an addition to existing insulin treatment, not as an insulin replacement. | Amylin and insulin affect different parts of meal-related glucose regulation. Pramlintide does not take over insulin's role. | The approved product is an adjunct to mealtime insulin, not a substitute. |
| Weight change in a trial means pramlintide is approved for obesity. | In one insulin-treated type 2 diabetes trial, mean weight in the 120 mcg twice-daily group fell by 1.4 kg over 52 weeks, while the placebo group gained 0.7 kg on average. | That result belongs to the studied diabetes population. The US label does not list weight loss as an indication. | |
| Pramlintide is the same kind of medicine as a GLP-1 agonist. | Pramlintide is an analogue of amylin. The label describes effects on gastric emptying, post-meal glucagon, and satiety. | It is an amylin analogue. Similar discussion of appetite does not make its identity, indication, or dosing interchangeable with a GLP-1 drug. |
Bottom line
Main takeaway
This is a prescribed add-on for certain people using mealtime insulin. Its most serious labeled concern is severe low blood sugar when used with insulin.
Separate the approved diabetes indication from trial weight outcomes, and separate an amylin analogue from a GLP-1 receptor agonist.
Two randomized diabetes trials and the US product label provide direct evidence. The older trial schedules do not reproduce the current label initiation instructions.
Identity
What it is
Pramlintide is a synthetic 37-amino-acid analogue of human amylin. The SYMLIN label describes a prescription injection in a pen formulation.
Amylin is released from pancreatic beta cells with insulin in response to food. Pramlintide is used alongside, rather than in place of, mealtime insulin in its labeled setting.
Use context
Routes, doses, and cycle patterns
SYMLIN is injected before major meals, with different starting doses for type 1 and type 2 diabetes. Its label calls for clinician-directed insulin adjustments and frequent glucose monitoring.
Human studies and product labels
US label, type 1 diabetes
- Purpose
- Adjunct to mealtime insulin
- Context
- Approved product labeling
- Route
- Subcutaneous
- Amount
- 15 mcg initially, with increments to 30, 45, or 60 mcg after at least 3 days without significant nausea
- Frequency
- Immediately before each major meal
The label defines a major meal as at least 250 kcal or 30 g of carbohydrate. It calls for an initial 50% reduction in mealtime insulin and frequent glucose monitoring, with further adjustments directed by a clinician. SYMLIN and insulin are separate injections and must not be mixed.
US label, type 2 diabetes
- Purpose
- Adjunct to mealtime insulin
- Context
- Approved product labeling
- Route
- Subcutaneous
- Amount
- 60 mcg initially, with an increase to 120 mcg after at least 3 days without significant nausea
- Frequency
- Immediately before each major meal
The same label calls for an initial 50% reduction in mealtime insulin and frequent glucose monitoring. Insulin and pramlintide changes need clinician direction.
Type 1 diabetes randomized trial
- Purpose
- Study of glucose control with existing insulin
- Context
- Randomized trial alongside insulin
- Route
- Subcutaneous
- Amount
- 30 mcg initially; selected participants later received 30 or 60 mcg
- Frequency
- Four times daily, described as preprandial injections
- Duration
- 52-week randomized phase
At week 20, participants whose HbA1c had fallen by less than one percentage point at week 13 were re-randomized to 30 or 60 mcg.
Type 2 diabetes randomized trial
- Purpose
- Study of glucose control with existing insulin
- Context
- Randomized trial alongside insulin
- Route
- Subcutaneous
- Amount
- 120 mcg in one study arm
- Frequency
- Twice daily before meals in that arm
- Duration
- 52 weeks
Other trial arms received 60 mcg three times daily or 90 mcg twice daily.
What varies
- The US label uses different starting amounts for type 1 and type 2 diabetes and sets conditions for dose increases based on tolerability.
- The label calls for frequent glucose checks, particularly when starting treatment or increasing the dose, and states that insulin adjustments should be directed by a qualified clinician.
Research
Research evidence
Randomized trials in people already using insulin showed improvements in HbA1c with pramlintide compared with placebo. In the type 2 diabetes trial, mean weight decreased in one pramlintide group and increased in the placebo group. The SYMLIN label warns of severe hypoglycemia when used with insulin.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Type 1 diabetes adjunctive trial | 480 people with type 1 diabetes using insulin | Randomized, double-blind, placebo-controlled trial with an optional open-label extension | Pramlintide added to insulin | Mean HbA1c fell 0.67 percentage points from baseline at week 13 with pramlintide versus 0.16 points with placebo. A significant difference remained through week 52. | The extension was open-label and included only some randomized-phase completers. The trial schedule differs from label initiation. | Strong for the studied diabetes population |
| Type 2 diabetes adjunctive trial | 656 insulin-treated people with type 2 diabetes | Randomized, double-blind, placebo-controlled trial | Pramlintide added to insulin, sometimes with oral diabetes medicines | In the 120 mcg twice-daily group, mean HbA1c fell 0.62 percentage points from baseline at week 52. Mean weight changed by minus 1.4 kg compared with a 0.7 kg gain with placebo. | Participants had insulin-treated type 2 diabetes. The US label starts treatment at 60 mcg before each major meal. | Strong for the studied diabetes population |
Cautions
Safety and unknowns
- The boxed warning concerns severe hypoglycemia when SYMLIN is used with insulin, particularly in type 1 diabetes. A severe episode can cause injury during driving or other hazardous activity.
- The product is contraindicated with hypoglycemia unawareness, confirmed gastroparesis, or prior serious hypersensitivity to SYMLIN or its ingredients. Nausea, vomiting, reduced appetite, and headache are common labeled adverse reactions.
- The label's patient-selection guidance says not to consider patients with HbA1c above 9% or recurrent severe hypoglycemia requiring assistance in the previous six months. It lists additional selection criteria as well.
- Slower gastric emptying can affect oral medicines where timing of absorption matters. The label advises specific timing for some oral medications; review other medicines with the prescriber.
- Pediatric safety and effectiveness are not established, and the label says use in children is not recommended because of severe hypoglycemia risk.
Product quality
Product identity and quality
The SYMLIN label describes a specific prescription pen formulation. AstraZeneca reports that US production and supply of SymlinPen have been discontinued. A substance name alone does not establish the identity or concentration of another product.
Mechanism
How it is proposed to work
Pramlintide mimics some meal-related effects of amylin: food leaves the stomach more slowly, the post-meal rise in glucagon is reduced, and fullness can increase.
FAQ
Common questions
Is pramlintide a replacement for insulin?
No. SYMLIN is used alongside mealtime insulin in selected patients. Insulin and pramlintide adjustments require guidance from a clinician skilled in insulin use.
Is pramlintide approved for weight loss?
The US SYMLIN label describes an adjunctive diabetes indication, not a weight-loss indication. Weight change in a diabetes trial is not a separate approval.
Is SymlinPen available in the US?
AstraZeneca reports that US production and supply of SymlinPen have been discontinued and remaining inventory is expected to run out. FDA records the product's approval history separately from its discontinued marketing status. Local pharmacy stock has not been verified here.
What is the main safety warning?
The label warns of severe hypoglycemia when used with insulin, especially in type 1 diabetes. The full label says episodes associated with SYMLIN usually occur within the first 2 to 3 hours after injection; this is not a guaranteed safety window.
Details
Technical details
Sources
References
- 1.
DailyMed. SYMLIN prescribing information
Official US label for indications, administration, contraindications, warnings, and pharmacology.
- 2.
AstraZeneca US Patient Support. SymlinPen US production and supply notice
The manufacturer reports discontinued US production and supply and expects remaining inventory to run out.
- 3.
FDA. SYMLIN product and approval history, NDA 021332
FDA records the product's approval history and lists its formulations with discontinued marketing status.
- 4.
doi:10.2337/diacare.25.4.724 PMID:11919132
Randomized type 1 diabetes trial with a subsequent open-label extension.
- 5.
doi:10.2337/diacare.26.3.784 PMID:12610038
Randomized, placebo-controlled trial in insulin-treated adults with type 2 diabetes.